| -0.04 / -0.51%|
Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA.
|Jeffrey L. Stein, PhD||President, Chief Executive Officer & Director|
|John P. Schmid, MBA||Chief Financial Officer & Secretary|
|John Finn, PhD||Chief Scientific Officer|
|Philippe G. Prokocimer, MD, PhD||Chief Medical Officer|
|Michael Morneau, MBA, CPA||Chief Accounting Officer & Vice President|